56 related articles for article (PubMed ID: 38459416)
1. Multimodal Approaches to Patient Selection for Pancreas Cancer Surgery.
Muaddi H; Kearse L; Warner S
Curr Oncol; 2024 Apr; 31(4):2260-2273. PubMed ID: 38668070
[TBL] [Abstract][Full Text] [Related]
2. A single center experience in resectable pancreatic ductal adenocarcinoma : the limitations of the surgery-first approach. Critical review of the literature and proposals for practice update.
Dumont R; Puleo F; Collignon J; Meurisse N; Chavez M; Seidel L; Gast P; Polus M; Loly C; Delvenne P; Meunier P; Hustinx R; Deroover A; Detry O; Louis E; Martinive P; Van Daele D
Acta Gastroenterol Belg; 2017; 80(4):451-461. PubMed ID: 29560639
[TBL] [Abstract][Full Text] [Related]
3. Contemporary management of borderline resectable pancreatic ductal adenocarcinoma.
Lekka K; Tzitzi E; Giakoustidis A; Papadopoulos V; Giakoustidis D
Ann Hepatobiliary Pancreat Surg; 2019 May; 23(2):97-108. PubMed ID: 31225409
[TBL] [Abstract][Full Text] [Related]
4. Very Early Recurrence After Curative Resection for Pancreatic Ductal Adenocarcinoma: Proof of Concept for a "Biological R2 Definition".
Belfiori G; Crippa S; Pagnanelli M; Gasparini G; Aleotti F; Camisa PR; Partelli S; Pecorelli N; De Stefano F; Schiavo Lena M; Palumbo D; Tamburrino D; Reni M; Falconi M
Ann Surg Oncol; 2024 Jun; 31(6):4084-4095. PubMed ID: 38459416
[TBL] [Abstract][Full Text] [Related]
5. Poorly differentiated resectable pancreatic cancer: is upfront resection worthwhile?
Crippa S; Partelli S; Zamboni G; Barugola G; Capelli P; Inama M; Bassi C; Pederzoli P; Falconi M
Surgery; 2012 Sep; 152(3 Suppl 1):S112-9. PubMed ID: 22766365
[TBL] [Abstract][Full Text] [Related]
6. Risk factors for early recurrence in patients with pancreatic ductal adenocarcinoma who underwent curative resection.
Murakawa M; Kawahara S; Takahashi D; Kamioka Y; Yamamoto N; Kobayashi S; Ueno M; Morimoto M; Sawazaki S; Tamagawa H; Ohshima T; Yukawa N; Rino Y; Morinaga S
World J Surg Oncol; 2023 Aug; 21(1):263. PubMed ID: 37620940
[TBL] [Abstract][Full Text] [Related]
7. Impact of Tumor Size on the Outcomes of Patients with Resectable Distal Pancreatic Cancer: Lessons Learned from a Series of 158 Radical Resections.
Watanabe G; Ushida Y; Oba A; Ono Y; Sato T; Inoue Y; Takahashi Y; Saiura A; Ito H
Ann Surg Oncol; 2022 Jan; 29(1):378-388. PubMed ID: 34403004
[TBL] [Abstract][Full Text] [Related]
8. Neoadjuvant therapy offers longer survival than upfront surgery for poorly differentiated and higher stage pancreatic cancer.
Nurmi A; Mustonen H; Parviainen H; Peltola K; Haglund C; Seppänen H
Acta Oncol; 2018 Jun; 57(6):799-806. PubMed ID: 29241394
[TBL] [Abstract][Full Text] [Related]
9. Pancreatectomy with venous vascular resection for pancreatic cancer: Impact of types of vein resection on timing and pattern of recurrence.
Tamburrino D; Belfiori G; Andreasi V; Provinciali L; Cerchione R; De Stefano F; Fermi F; Gasparini G; Pecorelli N; Partelli S; Crippa S; Falconi M
Eur J Surg Oncol; 2023 Aug; 49(8):1457-1465. PubMed ID: 37088601
[TBL] [Abstract][Full Text] [Related]
10. Neoadjuvant Chemoradiotherapy Versus Upfront Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Long-Term Results of the Dutch Randomized PREOPANC Trial.
Versteijne E; van Dam JL; Suker M; Janssen QP; Groothuis K; Akkermans-Vogelaar JM; Besselink MG; Bonsing BA; Buijsen J; Busch OR; Creemers GM; van Dam RM; Eskens FALM; Festen S; de Groot JWB; Groot Koerkamp B; de Hingh IH; Homs MYV; van Hooft JE; Kerver ED; Luelmo SAC; Neelis KJ; Nuyttens J; Paardekooper GMRM; Patijn GA; van der Sangen MJC; de Vos-Geelen J; Wilmink JW; Zwinderman AH; Punt CJ; van Tienhoven G; van Eijck CHJ;
J Clin Oncol; 2022 Apr; 40(11):1220-1230. PubMed ID: 35084987
[TBL] [Abstract][Full Text] [Related]
11. Cancer statistics, 2022.
Siegel RL; Miller KD; Fuchs HE; Jemal A
CA Cancer J Clin; 2022 Jan; 72(1):7-33. PubMed ID: 35020204
[TBL] [Abstract][Full Text] [Related]
12. The impact of preoperative anemia on pancreatic resection outcomes.
Pecorelli N; Guarneri G; Quattromani R; Arru GG; Gozzini L; Lee YH; Vallorani A; Turi S; Partelli S; Crippa S; Falconi M
HPB (Oxford); 2022 May; 24(5):717-726. PubMed ID: 34702625
[TBL] [Abstract][Full Text] [Related]
13. Long-Term Survivors after Upfront Resection for Pancreatic Ductal Adenocarcinoma: An Actual 5-Year Analysis of Disease-Specific and Post-Recurrence Survival.
Belfiori G; Crippa S; Francesca A; Pagnanelli M; Tamburrino D; Gasparini G; Partelli S; Andreasi V; Rubini C; Zamboni G; Falconi M
Ann Surg Oncol; 2021 Dec; 28(13):8249-8260. PubMed ID: 34258720
[TBL] [Abstract][Full Text] [Related]
14. Predictors of early recurrence following neoadjuvant chemotherapy and surgical resection for localized pancreatic adenocarcinoma.
Narayanan S; AlMasri S; Zenati M; Nassour I; Chopra A; Rieser C; Smith K; Oyefusi V; Daum T; Bahary N; Bartlett D; Lee K; Zureikat A; Paniccia A
J Surg Oncol; 2021 Sep; 124(3):308-316. PubMed ID: 33893740
[TBL] [Abstract][Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
